Abstract
Purpose: To investigate the effect of mirabegron 50 mg/daily for JJ
stent-related symptoms after ureteroscopic stone surgery. Methods:
Medical records of 145 patients who were given a single daily oral dose
of 50 mg of mirabegron for relieving stent-related symptoms were
retrospectively analyzed. Demographic and clinical data and stone
parameters were recorded. All participants completed the Turkish version
of the Ureter Symptom Score Questionnaire (USSQ-T) on the postoperative
seventh day, and again after at least three weeks, before JJ stent
removal. The severity of stent-related symptoms was statistically
compared before and after the mirabegron treatment. Results: The mean
urinary symptoms score decreased significantly from 30.87 ± 9.43 to
22.61 ± 6.78 (p < 0.0001), mean body pain score decreased
significantly from 21.82 ± 11.22 to 14.03 ± 7.52 (p < 0.0001),
mean work performance score decreased from 10.50 ± 8.61 to 7.02 ± 6.51
(p < 0.0001), and mean general health score decreased
significantly from 15.43 ± 6.50 to 11.12 ± 3.70 (p < 0.0001).
The mean sexual matters score significantly decreased from 3.88 ± 3.40
to 2.48 ± 2.03 (p < 0.0001), the additional problem score
decreased from 9.31 ± 4.61 to 6.51 ± 2.83 (p < 0.0001), and
the overall quality of life (QoL) score decreased from 5.18 ± 1.94 to
4.23 ± 1.71 after mirabegron use (p < 0.0001). Conclusion:
Daily use of 50g of mirabegron significantly improved stent-related
symptoms, sexual matters, and quality of life.